{"title":"Perspectives on Neuroscience and Behavior.","authors":"","doi":"10.1177/10738584231166318","DOIUrl":null,"url":null,"abstract":"A recent review discussed the evidence that I N i -methyl-d-aspartate receptor (NMDA) hypofunction, neuroimmune dysregulation, and mitochondrial energy metabolism acted through a \"central hub\" of oxidative stress that resulted in impaired oligodendrocytes and parvalbumin-GABAergic neuron microcircuits that produce the impaired neural synchronization and cognitive, emotional, and social deficits seen in schizophrenia (Cuenod and others 2022) Now, genome-wide polygenic risk scores (GW-PRSs) and pathway-specific polygenic risk scores (PRSs) have been studied in two samples of first episode of psychosis patients. Oxidative stress was the only one of the five pathways that showed significant enrichment in both sample 1 ( I P i <.03) and sample 2 ( I P i <.002) in Oxidative stress and psychosis, (Pistis and others 2022). Now, it has been found that increased neuropsychiatric symptoms correlate with the increased blood oxidative stress toxicity (OSTOX)/antioxidant (ANTIOX) ratio ( I r i SP 2 sp = 0.186) in 120 patients with long COVID and 36 controls. [Extracted from the article] Copyright of Neuroscientist is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)","PeriodicalId":49753,"journal":{"name":"Neuroscientist","volume":"29 3","pages":"272"},"PeriodicalIF":3.5000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroscientist","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10738584231166318","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
A recent review discussed the evidence that I N i -methyl-d-aspartate receptor (NMDA) hypofunction, neuroimmune dysregulation, and mitochondrial energy metabolism acted through a "central hub" of oxidative stress that resulted in impaired oligodendrocytes and parvalbumin-GABAergic neuron microcircuits that produce the impaired neural synchronization and cognitive, emotional, and social deficits seen in schizophrenia (Cuenod and others 2022) Now, genome-wide polygenic risk scores (GW-PRSs) and pathway-specific polygenic risk scores (PRSs) have been studied in two samples of first episode of psychosis patients. Oxidative stress was the only one of the five pathways that showed significant enrichment in both sample 1 ( I P i <.03) and sample 2 ( I P i <.002) in Oxidative stress and psychosis, (Pistis and others 2022). Now, it has been found that increased neuropsychiatric symptoms correlate with the increased blood oxidative stress toxicity (OSTOX)/antioxidant (ANTIOX) ratio ( I r i SP 2 sp = 0.186) in 120 patients with long COVID and 36 controls. [Extracted from the article] Copyright of Neuroscientist is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)
期刊介绍:
Edited by Stephen G. Waxman, The Neuroscientist (NRO) reviews and evaluates the noteworthy advances and key trends in molecular, cellular, developmental, behavioral systems, and cognitive neuroscience in a unique disease-relevant format. Aimed at basic neuroscientists, neurologists, neurosurgeons, and psychiatrists in research, academic, and clinical settings, The Neuroscientist reviews and updates the most important new and emerging basic and clinical neuroscience research.